- Live Conference Call and Webcast at
4:30 PM ET -
PALO
ALTO, Calif., Oct. 24,
2022 /PRNewswire/ -- Eiger BioPharmaceuticals,
Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical
company focused on the development of innovative therapies for
hepatitis delta virus (HDV) and other serious diseases, today
announced that it will host a conference call on Thursday,
November 3, 2022 at 4:30 PM ET to discuss its third
quarter 2022 financial results and provide a business update.
The live and replayed webcast of the call will be available
through the company's website at www.eigerbio.com. To participate
in the live call by phone, please register in advance at
https://register.vevent.com/register/BI87b8efa326b64c63bd59eabef4f465ab to
receive the dial-in number and unique passcode to access the call.
The webcast will be archived and available for replay for at least
90 days after the event.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on
the development of innovative therapies for hepatitis delta virus
(HDV) and other serious rare diseases. The Eiger HDV platform
includes two first-in-class therapies in Phase 3 that target
critical host processes involved in viral replication. All five
Eiger rare disease programs have been granted FDA breakthrough
therapy designation.
For additional information about Eiger and its
clinical programs, please visit www.eigerbio.com.
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-third-quarter-2022-financial-results-and-business-update-on-thursday-november-3-301657595.html
SOURCE Eiger BioPharmaceuticals, Inc.